This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Johnson, I. S Search for Related Content PubMed PubMed Citation Articles by Johnson, I. S Social Bookmarking                   What's this?

Use of bisphosphonates for the treatment of metastatic bone pain. A survey of palliative physicians in the UK

A postal survey of palliative physicians in the UK conducted in 1999 demonstrated widespread use of bisphosphonates for treatment of bone metastases from a variety of tumour types. In the absence of clear guidelines, however, there was found to be wide variation in treatment regimes, and opinions about efficacy varied greatly between respondents. Pamidronate was the most popular choice of drug, but a number of respondents chose to use clodronate, often on the basis of cost saving. A high level of uncertainty about how to monitor side-effects and efficacy was revealed. As well as acute treatment of severe pain, a significant number of respondents reported treating patients prophylactically, and the majority thought that their use of bisphosphonates would increase over the next 2 years. The potential financial consequences of this are considered.

Key Words: bisphosphonates • bone metastases • survey • palliative care

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Botteman, V. Barghout, J. Stephens, J. Hay, J. Brandman, and M. Aapro Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases Ann. Onc., July 1, 2006; 17(7): 1072 - 1082. [Abstract] [Full Text] [PDF]